Open AccessPrognostic values of long noncoding RNA PVT 1 in various carcinomas: An updated systematic review and meta‐analysis
Author(s) -
Xiao Meizhu,
Feng Ying,
Liu Chongdong,
Zhang Zhenyu
Publication year - 2018
Publication title -
cell proliferation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.647
H-Index - 74
eISSN - 1365-2184
pISSN - 0960-7722
DOI - 10.1111/cpr.12519
Subject(s) - pvt1 , hazard ratio , long non coding rna , microrna , biomarker , oncology , metastasis , confidence interval , cancer , medicine , cancer research , downregulation and upregulation , biology , gene , genetics
Abstract Cancers have been a worldwide health problem with a high mortality rate, but ideal biomarkers are not available to effectively screen and diagnose patients. Currently, an increasing number of long noncoding RNA s have been reported to be abnormally expressed in human carcinomas and play a vital role in tumourigenesis. Plasmacytoma variant translocation 1 ( PVT 1) is upregulated in various carcinomas, and its overexpression is associated with poor survival in cancer patients. We conduct an updated meta‐analysis to determine its potential in prognosis for tumours. In total, 14 studies comprising 2435 patients were enrolled according to Reporting Recommendations for Tumour Marker Prognostic Studies guidelines. High PVT 1 expression indicated poor overall survival (hazard ratio [ HR ] = 1.98, 95% confidence interval [ CI ]: 1.62‐2.42, P < 0.00001) and disease‐free survival ( HR = 1.63, 95% CI : 1.45‐1.84, P < 0.00001). Additionally, increased PVT 1 expression was positively associated with lymphatic node metastasis (odd ratio [ OR ] = 2.87, 95% CI : 1.66‐4.96, P = 0.0002), distant metastasis ( OR = 2.47, 95% CI : 1.74‐3.50, P < 0.00001), advanced tumour‐node‐metastasis stages ( OR = 2.59, 95% CI : 1.38‐4.88, P = 0.003). New findings highlight that PVT 1 acts as competing RNA to micro RNA s to protect mRNA s from mi RNA s repression. Therefore, we also discuss PVT 1‐related micro RNA s and their interaction in tumourigenesis. In conclusion, PVT 1 may be a potential biomarker of poor prognosis for patients with different cancer types.